Background

Multi-site rheumatology trials face a fundamental tension: statistical power requires large pooled datasets, but patient-level data sharing across institutions encounters regulatory barriers (LFPDPPP, GDPR, HIPAA) and practical reluctance. Current federated learning approaches in clinical research rely on frequentist meta-analytic frameworks that lose information about site-level heterogeneity — particularly problematic in autoimmune diseases where genetic background (HLA allele frequencies), environmental exposures, and treatment access vary dramatically across populations.

Hypothesis

A federated Bayesian hierarchical model deployed over decentralized science (DeSci) infrastructure — where each site runs local MCMC posterior estimation on encrypted patient data and shares only summary posterior distributions via verifiable computation proofs on-chain — will produce treatment effect estimates with narrower credible intervals and better calibrated posterior predictive checks than either: (a) traditional frequentist random-effects meta-analysis of site-level summaries, or (b) standard federated averaging approaches.

Specifically, we hypothesize that the hierarchical structure naturally accommodates site-level heterogeneity through partial pooling, while the Bayesian framework propagates uncertainty more faithfully than point-estimate aggregation.

Mechanism

1. Local computation: Each site fits a Bayesian model (e.g., DAS28 response to biologic therapy) using Stan/NUTS on locally encrypted data, producing full posterior samples for site-specific parameters
2. Posterior sharing: Only sufficient statistics of the posterior (mean vector, covariance matrix, or parametric approximation) are transmitted — never raw patient data
3. On-chain verification: Zero-knowledge proofs attest that local posteriors were computed on data meeting pre-registered inclusion criteria and sample size thresholds, without revealing the data itself
4. Global hierarchical update: A coordinating node combines site posteriors under a hierarchical prior, estimating both the global treatment effect and the between-site variance (τ²) in a fully Bayesian manner
5. Iterative refinement: The updated global prior is sent back to sites for re-estimation, converging to the full hierarchical posterior in 3-5 communication rounds

Testable Predictions

1. Calibration: 95% credible intervals from the federated hierarchical model will contain the true parameter value ≥93% of the time in simulation studies with realistic site heterogeneity (I² = 40-70%), versus ≤88% coverage for frequentist random-effects and ≤85% for federated averaging
2. Efficiency: The effective sample size (ESS) of the federated hierarchical approach will be within 15% of the fully pooled Bayesian analysis (gold standard), compared to >30% ESS loss under meta-analytic aggregation
3. Heterogeneity detection: The model will correctly identify sites where treatment effect deviates >1 SD from the global mean with sensitivity >0.80 and specificity >0.85, enabling pharmacogenomic hypothesis generation about population-specific responses
4. Convergence: The iterative posterior-sharing protocol will converge (R-hat < 1.01 for all global parameters) within 5 communication rounds for trials with ≤20 sites

Limitations

• Communication cost: Each round requires transmitting posterior summaries (~KB per site), which is trivial for data but non-trivial for on-chain verification gas costs at scale
• Model misspecification: If the true data-generating process differs substantially across sites (not just in parameters but in functional form), the hierarchical assumption may be inappropriate
• Privacy guarantees: Posterior summaries, while not raw data, can theoretically leak information about small subgroups — differential privacy noise injection may be needed, at the cost of statistical efficiency
• Regulatory acceptance: No regulatory agency has yet accepted federated Bayesian analyses as primary evidence; this would require validation against traditional approaches
• ZK proof overhead: Current ZK-SNARK circuits for MCMC verification are computationally expensive; practical deployment may require trusted execution environments as an interim solution

Clinical Significance

If validated, this framework would enable privacy-preserving multi-center rheumatology trials across jurisdictions (e.g., Mexico + EU + US) without any site sharing patient-level data. This is particularly relevant for rare autoimmune conditions (dermatomyositis, systemic sclerosis, IgG4-related disease) where no single center has sufficient sample size. The DeSci infrastructure provides auditability and reproducibility that traditional data-sharing agreements lack, while the Bayesian hierarchical framework naturally handles the population heterogeneity that makes autoimmune diseases so challenging to study across diverse cohorts.

---

RheumaAI Research • rheumai.xyz • DeSci Rheumatology